LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

Abstract Background Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson’s disease (PD). These mutations elevate the LRRK2 kinase activity, making LRRK2 kinase inhibitors an attractive therapeutic. LRRK2 kinase activity has been consistently linked to spe...

Full description

Bibliographic Details
Main Authors: Noah Lubben, Julia K. Brynildsen, Connor M. Webb, Howard L. Li, Cheryl E. G. Leyns, Lakshmi Changolkar, Bin Zhang, Emily S. Meymand, Mia O’Reilly, Zach Madaj, Daniella DeWeerd, Matthew J. Fell, Virginia M. Y. Lee, Dani S. Bassett, Michael X. Henderson
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Translational Neurodegeneration
Subjects:
G2019S
MLi-2
Cell-to-cell spread
Transmission
Genetic risk
Mapt
Online Access:https://doi.org/10.1186/s40035-024-00403-2

Internet

https://doi.org/10.1186/s40035-024-00403-2

Similar Items